Please assess the completion status of the following clinical trial:

Trial Title: Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥18 and \<75 years of age at the time of consent~* Physician diagnosis of asthma for ≥12 months (relative to Baseline) based on Global Initiative for Asthma (GINA) 2018 Guidelines~* Asthma requiring treatment with, at a minimum, low dose inhaled corticosteroids in combination with a long-acting β2 agonist, on a stable dose for at least 1 month before Screening~* Bronchodilator reversibility, as evidenced by ≥12% and ≥200 mL improvement in FEV1 15 to 25 minutes following inhalation of albuterol at Screening~* Pre-bronchodilator FEV1 ≥40% and \<80% of predicted at Screening and Baseline~* AEC ≥0.30 x10\^9/L at the Screening visit~* ACQ-7 ≥1.5 at Screening~* Negative pregnancy test at Baseline~* Adherence ≥85% with twice-daily placebo taken during the Run-in Period~Exclusion Criteria:~* Treatment for an asthma exacerbation within 8 weeks prior to Baseline visit~* Treatment with systemic corticosteroids in the 8 weeks prior to Screening~* Treatment with monoclonal antibody therapy, within 5-half-lives prior to Baseline~* Treatment with selected drugs known to have a substantial risk of neutropenia~* Absolute neutrophil count \<2.0x10\^9/L at Screening, or any documented history of absolute neutrophil count \<2.0x10\^9/L.~* Renal dysfunction, defined as an estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73m\^2 at Screening~* Clinically significant abnormal laboratory or ECG values~* Other medically significant illness~* Use of any smoke or inhaled nicotine delivery device within 1 year prior to Screening~* Pregnant women or women breastfeeding~* Currently taking pramipexole or other dopamine agonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- placebo BID (Type: PLACEBO_COMPARATOR): Following a 2-4 week placebo run-in, randomized subjects received 1 tablet placebo twice daily for 12 weeks.
- 37.5 mg BID dexpramipexole (Type: ACTIVE_COMPARATOR): Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 37.5 mg dexpramipexole twice daily for 12 weeks.
- 75 mg BID dexpramipexole (Type: ACTIVE_COMPARATOR): Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 75 mg dexpramipexole twice daily for 12 weeks.
- 150 mg BID dexpramipexole (Type: ACTIVE_COMPARATOR): Following a 2-4 week placebo run-in, randomized subjects received 1 tablet of 150 mg dexpramipexole twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).